Johnson & Johnson has agreed to pay a record $181 million to settle claims brought by New York and 36 other states that the company’s Janssen Pharmaceuticals unit improperly marketed Risperdal and other anti-psychotic drugs for “off-label” uses.
“Pharmaceutical corporations’ illegal promotion of drugs for off-label uses must stop,” New » […]
Original post by http://lawyersusaonline.com/blog/2012/09/05/jj-unit-settles-state-risperdal-claims-for-181m/
Report bad drivers!